Randomized controlled trial design in rheumatoid arthritis: the past decade
Open Access
- 1 January 2009
- journal article
- review article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 11 (1) , 205
Abstract
Much progress has occurred over the past decade in rheumatoid arthritis trial design. Recognized challenges have led to the establishment of a clear regulatory pathway to demonstrate efficacy of a new therapeutic. The use of pure placebo beyond 12 to 16 weeks has been demonstrated to be unethical and thus background therapy and/or early rescue has become regular practice. Goals of remission and 'treating to targets' may prove more relevant to identify real-world use of new and existing therapeutics. Identification of rare adverse events associated with new therapies has resulted in intensive safety evaluation during randomized controlled trials and emphasis on postmarketing surveillance and use of registries.Keywords
This publication has 61 references indexed in Scilit:
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnnals of the Rheumatic Diseases, 2009
- Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritisAmerican Heart Journal, 2008
- Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis CohortThe American Journal of Medicine, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritisRheumatology, 2004
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Efficacy of Low-Dose Methotrexate in Rheumatoid ArthritisNew England Journal of Medicine, 1985